Literature DB >> 6160014

Kinetics of N-acetylprocainamide deacetylation.

G P Stec, T I Ruo, J P Thenot, A J Atkinson, Y Morita, J J Lertora.   

Abstract

The kinetics of N-acetylprocainamide (NAPA) deacetylation to procainamide (PA) were determined in a normal subject using NAPA-13C, labeled in the acetyl group. The deacetylation clearance of NAPA (ClD) was found to be 6.5 ml/min whereas total NAPA elimination clearance was 231 ml/min, so that 2.8% of the administered NAPA-13C was metabolized by deacetylation. This estimated of ClD was shown to be representative of the rate of NAPA deacetylation in four patients on long-term NAPA therapy. Steady-state [PA]/[NAPA] ratios averaged 0.024, but would be expected to rise to 0.057 if functionally anephric patients were treated with NAPA. Despite reports that patients with the PA-induced systemic lupus erythematosus-like reaction have had symptomatic and immunologic remission when switched to NAPA, the demonstration that NAPA is deacetylated to PA indicates that the apparently greater immunologic safety of NAPA may be relative rather than absolute.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6160014     DOI: 10.1038/clpt.1980.218

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Ranitidine and procainamide absorption.

Authors:  A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

Review 2.  Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Is N-acetylation of 5-aminosalicylic acid reversible in man?

Authors:  C O Meese; C Fischer; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

4.  Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man.

Authors:  A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of N-acetylprocainamide.

Authors:  S J Connolly; R E Kates
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.